Hungary

BMI View: Our view on Egis PLC continues to play out. Forint weakness, tax allowances, greater generic uptake in the region and rising pharmaceutical expenditure in Russia and the Commonwealth... 2013-02-21

BMI View: We believe there is a compelling case for Egis' earnings growth, given its presence in export markets, continued weakness of the forint and the prime mover advantage in marketing... 2013-01-23

BMI View: Continued export growth and changes to tax allowances will provide a boost to Gedeon Richter's earnings in the coming year. The sales potential of Esmya and continued in-licensing... 2013-01-21

BMI View: The Hungarian government's harsh measures aimed at reducing its debt have severely affected the domestic market for pharmaceutical companies, with quarter-on-quarter declines... 2012-12-17

BMI View: Gedeon Richter's results parallel the Hungarian macroeconomic export story, with strong growth recorded in the EU and growing markets such as Russia, Ukraine and Poland. The... 2012-11-07

BMI View: As we have stated for more than 18 months, Egis' significant exposure to its domestic pharmaceutical market in Hungary will continue to damage its top- and bottom-line financials.[1][2]... 2012-08-09

BMI View: Hungarian pharmaceutical company Gedeon Richter has maintained its rather gloomy outlook for 2012 following the release of the financial results for the first half of the... 2012-08-03

BMI View: Drugmakers previously disheartened by the extent of cuts to Hungary's National Healthcare Fund (OEP) will be further aggrieved by a new bill that proposes increasing the levies... 2012-06-25

BMI View: Egis' significant exposure to its domestic pharmaceutical market in Hungary will continue to damage its top- and bottom-line financials over the coming quarters. It exposure... 2012-05-17

BMI View: Hungary's largest drugmaker, Gedeon Richter, has posted strong and above-consensus results for Q112, with profits benefiting from favourable exchange rates and two milestone... 2012-05-14